WO1997007784A3 - LIPOSOMAL PHOSPHODIESTER, PHOSPHOROTHIOATE, AND p-ETHOXY OLIGONUCLEOTIDES - Google Patents

LIPOSOMAL PHOSPHODIESTER, PHOSPHOROTHIOATE, AND p-ETHOXY OLIGONUCLEOTIDES Download PDF

Info

Publication number
WO1997007784A3
WO1997007784A3 PCT/US1996/014146 US9614146W WO9707784A3 WO 1997007784 A3 WO1997007784 A3 WO 1997007784A3 US 9614146 W US9614146 W US 9614146W WO 9707784 A3 WO9707784 A3 WO 9707784A3
Authority
WO
WIPO (PCT)
Prior art keywords
oligonucleotides
phosphodiester
phosphorothioate
liposomal
ethoxy
Prior art date
Application number
PCT/US1996/014146
Other languages
French (fr)
Other versions
WO1997007784A2 (en
Inventor
Gabriel Lopez-Berestein
Ana Maria Tari
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Priority to CA2228944A priority Critical patent/CA2228944C/en
Priority to DE69630691T priority patent/DE69630691T2/en
Priority to DK96929888T priority patent/DK0847272T3/en
Priority to AT96929888T priority patent/ATE253897T1/en
Priority to JP51064297A priority patent/JP4291412B2/en
Priority to AU69129/96A priority patent/AU6912996A/en
Priority to EP96929888A priority patent/EP0847272B1/en
Publication of WO1997007784A2 publication Critical patent/WO1997007784A2/en
Publication of WO1997007784A3 publication Critical patent/WO1997007784A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Abstract

An improved delivery system for antisense oligonucleotides involves a liposomal composition, comprising a liposome which consists essentially of neutral phospholipids and an antisense oligonucleotide that is entrapped in the liposome and is selected from the group consisting of phosphodiester oligonucleotides, phosphorothioate oligonucleotides, and p-ethoxy oligonucleotides.
PCT/US1996/014146 1995-08-29 1996-08-26 LIPOSOMAL PHOSPHODIESTER, PHOSPHOROTHIOATE, AND p-ETHOXY OLIGONUCLEOTIDES WO1997007784A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA2228944A CA2228944C (en) 1995-08-29 1996-08-26 Liposomal phosphodiester, phosphorothioate, and p-ethoxy oligonucleotides
DE69630691T DE69630691T2 (en) 1995-08-29 1996-08-26 Liposomal p-ethoxy oligonucleotides
DK96929888T DK0847272T3 (en) 1995-08-29 1996-08-26 Liposomal β-ethoxy oligonucleotides
AT96929888T ATE253897T1 (en) 1995-08-29 1996-08-26 LIPOSOMES WITH P-ETHOXYOLIGONUCLEOTIDES
JP51064297A JP4291412B2 (en) 1995-08-29 1996-08-26 Liposomal phosphodiester, phosphorothioate, and p-ethoxy oligonucleotides
AU69129/96A AU6912996A (en) 1995-08-29 1996-08-26 Liposomal phosphodiester, phosphorothioate, and p-ethoxy oligonucleotides
EP96929888A EP0847272B1 (en) 1995-08-29 1996-08-26 LIPOSOMAL p-ETHOXY OLIGONUCLEOTIDES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/520,385 1995-08-29
US08/520,385 US5855911A (en) 1995-08-29 1995-08-29 Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides

Publications (2)

Publication Number Publication Date
WO1997007784A2 WO1997007784A2 (en) 1997-03-06
WO1997007784A3 true WO1997007784A3 (en) 1997-04-24

Family

ID=24072378

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/014146 WO1997007784A2 (en) 1995-08-29 1996-08-26 LIPOSOMAL PHOSPHODIESTER, PHOSPHOROTHIOATE, AND p-ETHOXY OLIGONUCLEOTIDES

Country Status (11)

Country Link
US (4) US5855911A (en)
EP (1) EP0847272B1 (en)
JP (1) JP4291412B2 (en)
AT (1) ATE253897T1 (en)
AU (1) AU6912996A (en)
CA (1) CA2228944C (en)
DE (1) DE69630691T2 (en)
DK (1) DK0847272T3 (en)
ES (1) ES2210385T3 (en)
PT (1) PT847272E (en)
WO (1) WO1997007784A2 (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US6977244B2 (en) * 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US6894031B1 (en) * 1996-11-21 2005-05-17 Cedars-Sinai Medical Center Pituitary tumor transforming gene (PTTG) carboxy-terminal peptides and methods of use thereof to inhibit neoplastic cellular proliferation and/or transformation
US6565889B2 (en) * 1996-12-02 2003-05-20 The Regents Of The University Of California Bilayer structure which encapsulates multiple containment units and uses thereof
US7262173B2 (en) 1997-03-21 2007-08-28 Georgetown University Chemosensitizing with liposomes containing oligonucleotides
US6126965A (en) * 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
DE69841002D1 (en) 1997-05-14 2009-09-03 Univ British Columbia Highly effective encapsulation of nucleic acids in lipid vesicles
US6835395B1 (en) 1997-05-14 2004-12-28 The University Of British Columbia Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
EP1017365B1 (en) * 1997-06-23 2003-12-10 Sequus Pharmaceuticals, Inc. Liposome-entrapped polynucleotide composition and method
AU731909B2 (en) * 1997-07-01 2001-04-05 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
DE19740092A1 (en) * 1997-09-12 1999-03-18 Ulrich Dr Med Hengge New liposome comprises lipid envelope based on natural or synthetic skin
US7704962B1 (en) * 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
US7285288B1 (en) * 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
KR100820266B1 (en) 1999-02-26 2008-04-08 더 유니버시티 오브 브리티쉬 콜롬비아 TRPM-2 antisense therapy
US7112337B2 (en) 1999-04-23 2006-09-26 Alza Corporation Liposome composition for delivery of nucleic acid
WO2001026625A2 (en) 1999-10-08 2001-04-19 Alza Corp Neutral-cationic lipid for nucleic acid and drug delivery
FR2802422B1 (en) 1999-12-21 2002-08-09 Capsulis MIXED STRUCTURES RESULTING FROM THE INCORPORATION OF A BIOLOGICAL MACROMOLECULE, PARTICULARLY DNA, IN A STRUCTURED PHASE OF AMPHIPHILES AND VESICLES OBTAINED FROM THESE STRUCTURES
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
HU229207B1 (en) 2000-09-14 2013-09-30 Univ British Columbia Antisense insulin-like growth factor binding protein (igfbp)-2-oligodeoxynucleotides for prostate and other endocrine regulated tumor therapy
CA2471967A1 (en) * 2002-01-03 2003-07-31 Board Of Regents, The University Of Texas System Wt1 antisense oligos for the inhibition of breast cancer
DE60322509D1 (en) * 2002-01-17 2008-09-11 Univ British Columbia BIS-SPECIFIC ANTISENSE OLIGONUCLEOTIDES INHIBIT THE IGFBP-2 AND IGFBP-5 AND THEIR USE
WO2004018675A1 (en) 2002-08-21 2004-03-04 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
WO2004030660A2 (en) 2002-10-02 2004-04-15 The University Of British Columbia Compositions for treatment of prostate and other cancers
CA2520864A1 (en) 2003-03-31 2004-10-21 Alza Corporation Lipid particles having asymmetric lipid coating and method of preparing same
AU2003259832A1 (en) 2003-08-14 2005-03-10 Boston Scientific Limited Medical slings
CA2539727C (en) * 2003-10-01 2016-11-01 The University Of British Columbia Bispecific oligonucleotide for the treatment of cns malignancies
WO2005044998A2 (en) 2003-11-05 2005-05-19 Palingen, Inc. Enhanced b cell cytotoxicity of cdim binding antibody
EP1691780A2 (en) 2003-11-21 2006-08-23 Alza Corporation Gene delivery mediated by liposome-dna complex with cleavable peg surface modification
US8710020B2 (en) * 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
US8628465B2 (en) * 2004-06-14 2014-01-14 Boston Scientific Scimed, Inc. Systems, methods and devices relating to implantable supportive slings
EP1814913B1 (en) 2004-11-05 2015-08-19 IGM Biosciences, Inc. Antibody induced cell membrane wounding
WO2006056054A1 (en) * 2004-11-23 2006-06-01 The University Of British Columbia Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels
WO2006113679A2 (en) * 2005-04-15 2006-10-26 Board Of Regents, The University Of Texas System Delivery of sirna by neutral lipid compositions
ES2536748T3 (en) * 2005-04-06 2015-05-28 Boston Scientific Limited Systems and devices to treat pelvic floor disorders
EP1909687A1 (en) 2005-07-13 2008-04-16 Boston Scientific Scimed, Inc. Snap fit sling anchor system and related methods
EP2974692B1 (en) 2005-07-25 2019-03-13 Boston Scientific Limited Pelvic floor repair system
US7981023B2 (en) * 2005-07-25 2011-07-19 Boston Scientific Scimed, Inc. Elastic sling system and related methods
US8273429B2 (en) * 2006-01-19 2012-09-25 Federal-Mogul World Wide, Inc. Fabric for end fray resistance and protective sleeves formed therewith and methods of construction
FR2900576B1 (en) * 2006-05-03 2008-09-19 Centre Nat Rech Scient PROCESS FOR EXTEMPORANEOUS AND REVERSIBLE CONCENTRATION OF LIPOSOMES.
US9381209B2 (en) * 2007-03-05 2016-07-05 The University Of British Columbia Treatment of squamous cell carcinoma with HSP27 antisense oligonucleotides and radiotherapy
CN102112110A (en) * 2008-06-06 2011-06-29 米尔纳医疗股份有限公司 Novel compositions for the in vivo delivery of RNAi agents
ES2710109T3 (en) 2010-12-17 2019-04-23 Inst Nat Sante Rech Med Nucleic acids that target TCTP for use in the treatment of chemoresistant or hormone-resistant cancers
EP2741784B1 (en) 2011-03-02 2017-05-17 Board Of Regents, The University Of Texas System Tusc2 therapies
US9113991B2 (en) 2011-05-12 2015-08-25 Boston Scientific Scimed, Inc. Anchors for bodily implants and methods for anchoring bodily implants into a patient's body
US9636201B2 (en) 2011-05-12 2017-05-02 Boston Scientific Scimed, Inc. Delivery members for delivering an implant into a body of a patient
US9409976B2 (en) 2012-02-08 2016-08-09 Igm Biosciences, Inc. CDIM binding proteins and uses thereof
CN103565745A (en) 2012-08-10 2014-02-12 德克萨斯州大学系统董事会 Neuroprotective liposome compositions and methods for treatment of stroke
WO2014195755A1 (en) 2013-06-05 2014-12-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Hydrophobically modified antisense oligonucleotides comprising a ketal group
WO2014195754A1 (en) 2013-06-05 2014-12-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Hydrophobically modified antisense oligonucleotides comprising a triple alkyl chain
WO2017066643A1 (en) 2015-10-14 2017-04-20 Bio-Path Holding, Inc. P-ethoxy nucleic acids for liposomal formulation
US10736880B2 (en) 2015-12-18 2020-08-11 The Board Of Regents Of The University Of Texas Systems Therapeutics for preterm labor management
CN109789093A (en) * 2016-09-14 2019-05-21 南洋理工大学 Liposomal formulation
KR20190053905A (en) 2016-09-16 2019-05-20 바이오-패쓰 홀딩스 인크. Combination therapy with liposomal antisense oligonucleotides
MA46542A (en) 2016-10-12 2021-03-31 Univ Texas METHODS AND COMPOSITIONS FOR TUSC2 IMMUNOTHERAPY
AU2018254485A1 (en) * 2017-04-19 2019-10-31 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for IGF-1R inhibition
WO2018195249A1 (en) * 2017-04-19 2018-10-25 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for stat3 inhibition
CN110650727A (en) * 2017-04-19 2020-01-03 拜奥-帕斯控股股份有限公司 P-ethoxy nucleic acids for IGF-1R inhibition
AU2021260578A1 (en) 2020-04-20 2022-11-03 Board Of Regents, The University Of Texas System Biologically active dry powder compositions and method of their manufacture and use
US20230302154A1 (en) 2020-08-19 2023-09-28 The Board Of Regents Of The University Of Texas System Nanodrugs for targeted drug delivery and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4110085A1 (en) * 1991-03-27 1992-10-01 Boehringer Ingelheim Int New 2'O-alkyl-oligo-ribonucleotide(s) with 8-35 nucleotide units - useful as anti-sense oligo-nucleotide(s), primers and probes
WO1995003788A1 (en) * 1993-07-29 1995-02-09 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621479A5 (en) * 1977-08-05 1981-02-13 Battelle Memorial Institute
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4469863A (en) * 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4480041A (en) * 1982-07-09 1984-10-30 Collaborative Research, Inc. Use of phosphotriester intermediates for preparation of functionalized liposomes
FR2540122B1 (en) * 1983-01-27 1985-11-29 Centre Nat Rech Scient NOVEL COMPOUNDS COMPRISING A SEQUENCE OF OLIGONUCLEOTIDE LINKED TO AN INTERCALATION AGENT, THEIR SYNTHESIS PROCESS AND THEIR APPLICATION
US4721612A (en) * 1984-04-12 1988-01-26 The Liposome Company, Inc. Steroidal liposomes
US5202429A (en) * 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US5049388A (en) * 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US5094785A (en) * 1986-12-10 1992-03-10 Ciba Corning Diagnostics Corp. Process for stabilizing liposomes
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4920016A (en) * 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US5030442A (en) * 1987-03-30 1991-07-09 Liposome Technology, Inc. Non-crystalline minoxidil composition
US4904582A (en) * 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5178875A (en) * 1991-01-14 1993-01-12 The Board Of Regents, The University Of Texas System Liposomal-polyene preliposomal powder and method for its preparation
US4950432A (en) * 1987-10-16 1990-08-21 Board Of Regents, The University Of Texas System Polyene microlide pre-liposomal powders
US5188897A (en) * 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
US4924624A (en) * 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
EP0397774A1 (en) * 1988-02-04 1990-11-22 Board Of Regents, The University Of Texas System Formulation and use of retinoids in treatment of cancer and other diseases
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5831066A (en) * 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US5734033A (en) * 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
US5087617A (en) * 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5248671A (en) * 1989-02-15 1993-09-28 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
FR2644080A1 (en) * 1989-03-13 1990-09-14 Trizac Jacques DEVICE FOR FILTRATION AND EVACUATION OF SMALL PARTICLES, WASTES AND TRENDS OF VARIOUS NATURE
JP3010500B2 (en) * 1989-04-18 2000-02-21 ネクスター・フアーマシユーテイカルズ・インコーポレイテツド Liposomal targeting of ischemic tissue
US5112962A (en) * 1989-04-19 1992-05-12 Northwestern University Labile anchors for solid phase polynucleotide synthesis
US5227170A (en) * 1989-06-22 1993-07-13 Vestar, Inc. Encapsulation process
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
US5469854A (en) * 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
CA2033725C (en) * 1990-01-24 2001-05-29 Folker Pittrof Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
EP0527818A4 (en) * 1990-04-30 1993-09-15 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of arachidonic acid metabolism
US5665710A (en) * 1990-04-30 1997-09-09 Georgetown University Method of making liposomal oligodeoxynucleotide compositions
DK0464638T3 (en) * 1990-07-02 1997-10-13 Hoechst Ag Oligonucleotide analogs with terminal 3-3 or 5-5 internucleotide bonds.
US5135917A (en) * 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US5378825A (en) * 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
WO1992005272A1 (en) * 1990-09-17 1992-04-02 The Regents Of The University Of California Method and composition for controlling proliferation of cells
US5271941A (en) * 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
FR2677272B1 (en) * 1991-06-05 1995-03-03 Biovecteurs As PARTICULATE VECTOR WITH SELECTIVE TROPISM, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION.
JPH06508622A (en) * 1991-06-18 1994-09-29 テンプル　ユニバーシティ−オブ　ザ　コモンウェルス　システム　オブ　ハイヤーエデュケーション Selective inhibition of leukocyte proliferation by bcr-ab1 antisense oligonucleotide
US5525719A (en) * 1991-08-30 1996-06-11 Chemgenes Corporation N-protected-2'-O-methyl-and N-protected-3'-O-methyl-ribonucleosides and their phosphoramidite derivatives
ATE239484T1 (en) * 1991-10-24 2003-05-15 Isis Pharmaceuticals Inc DERIVATIZED OLIGONUCLEOTIDES WITH IMPROVED ABSORPTION CAPACITY
AU675923B2 (en) * 1991-12-04 1997-02-27 E.I. Du Pont De Nemours And Company Fatty acid desaturase genes from plants
US5279957A (en) * 1992-04-30 1994-01-18 Washington University cDNA encoding human phospholipase A2 polypeptide
IL105914A0 (en) * 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
US5320962A (en) * 1992-07-22 1994-06-14 Duke University DNA encoding the human A1 adenosine receptor
NL9201440A (en) * 1992-08-11 1994-03-01 Univ Leiden Triantennary cluster glycosides, their preparation and application.
AU5092893A (en) * 1992-09-02 1994-03-29 Georgetown University Method of encapsulating anthracycline glycosides in liposomes
US6001992A (en) 1999-01-07 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of novel anti-apoptotic bcl-2-related proteins
CA2147663A1 (en) 1992-10-21 1994-04-28 Bruno Calabretta Combination of antineoplastic agent and antisense oligonucleotides for treatment of cancer
US6015886A (en) * 1993-05-24 2000-01-18 Chemgenes Corporation Oligonucleotide phosphate esters
FR2710074B1 (en) * 1993-09-15 1995-12-08 Rhone Poulenc Rorer Sa GRB3-3 gene, its variants and their uses.
DK0678017T3 (en) * 1993-11-05 1998-10-19 Amgen Inc Liposome preparation and material encapsulation method
US5651981A (en) * 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
US5696248A (en) * 1994-06-15 1997-12-09 Hoechst Aktiengesellschaft 3'-modified oligonucleotide derivatives
US5908635A (en) * 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
IT1275862B1 (en) * 1995-03-03 1997-10-24 Consiglio Nazionale Ricerche ANTI-SENSE TRANSCRIPT ASSOCIATED WITH SOME TYPES OF TUMOR CELLS AND SYNTHETIC OLIGODEOXYNUCLEOTIDES USEFUL IN DIAGNOSIS AND TREATMENT
EP0739898B1 (en) * 1995-03-13 2001-09-26 Aventis Pharma Deutschland GmbH Phosphonomonoester nucleic acids, methods for their preparation and their use
WO1996038176A1 (en) * 1995-06-01 1996-12-05 Kishimoto, Tadamitsu Leukemic cell growth inhibitor containing antisense oligonucleotide derivative against wilms' tumor gene (wt1)
US6326487B1 (en) * 1995-06-05 2001-12-04 Aventis Pharma Deutschland Gmbh 3 modified oligonucleotide derivatives
US5756122A (en) * 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
JP4335310B2 (en) * 1995-06-07 2009-09-30 ザ ユニバーシティ オブ ブリティッシュ コロンビア Lipid-nucleic acid particles prepared through hydrophobic lipid-nucleic acid complex intermediates and use for gene transfer
US5705385A (en) * 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
DE69629702T2 (en) * 1995-08-01 2004-06-17 Isis Pharmaceuticals, Inc., Carlsbad LIPOSOMAL OLIGONUCLEOTIDE COMPOSITIONS
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
DE19532553A1 (en) * 1995-09-04 1997-03-06 Hoechst Ag Process for the preparation of substituted N-ethyl-glycine derivatives
US6120794A (en) * 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
US6977244B2 (en) * 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US5874224A (en) * 1997-03-11 1999-02-23 Incyte Pharmaceuticals, Inc. Growth factor receptor binding protein
US6126965A (en) * 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
GB9711919D0 (en) * 1997-06-09 1997-08-06 Ciba Geigy Ag Oligonucleotide derivatives
EP1017365B1 (en) * 1997-06-23 2003-12-10 Sequus Pharmaceuticals, Inc. Liposome-entrapped polynucleotide composition and method
WO1999001139A1 (en) * 1997-07-03 1999-01-14 Thomas Jefferson University An improved method for design and selection of efficacious antisense oligonucleotides
US7285288B1 (en) * 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US6136965A (en) * 1998-07-02 2000-10-24 The Regents Of The University Of California Deoxynucleic alkyl and alkoxy thiourea compounds
US6211162B1 (en) * 1998-12-30 2001-04-03 Oligos Etc. Inc. Pulmonary delivery of protonated/acidified nucleic acids
US6211349B1 (en) * 1998-12-30 2001-04-03 Oligos Etc., Inc. Protonated/acidified nucleic acids and methods of use
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4110085A1 (en) * 1991-03-27 1992-10-01 Boehringer Ingelheim Int New 2'O-alkyl-oligo-ribonucleotide(s) with 8-35 nucleotide units - useful as anti-sense oligo-nucleotide(s), primers and probes
WO1995003788A1 (en) * 1993-07-29 1995-02-09 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C.A. STEIN ET AL.: "antisense oligonucleotides as therapeutic agents-is the bullet really magical", SCIENCE, vol. 261, no. 5124, 20 August 1993 (1993-08-20), WASHINGTON (US), pages 1004 - 1012, XP002027216 *
S. AKHTAR ET AL.: "interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes)", NUCLEIC ACIDS RESEARCH, vol. 19, no. 20, 25 October 1991 (1991-10-25), EYNSHAM ,OXFORD (GB), pages 5551 - 5559, XP002027215 *

Also Published As

Publication number Publication date
ES2210385T3 (en) 2004-07-01
JP4291412B2 (en) 2009-07-08
US5855911A (en) 1999-01-05
JPH11512099A (en) 1999-10-19
AU6912996A (en) 1997-03-19
CA2228944A1 (en) 1997-03-06
CA2228944C (en) 2011-10-18
EP0847272A2 (en) 1998-06-17
US6042846A (en) 2000-03-28
DE69630691T2 (en) 2004-11-25
US20070202157A1 (en) 2007-08-30
US7176302B2 (en) 2007-02-13
US7754872B2 (en) 2010-07-13
DE69630691D1 (en) 2003-12-18
WO1997007784A2 (en) 1997-03-06
ATE253897T1 (en) 2003-11-15
US20040005353A1 (en) 2004-01-08
EP0847272B1 (en) 2003-11-12
PT847272E (en) 2004-04-30
DK0847272T3 (en) 2004-03-22

Similar Documents

Publication Publication Date Title
WO1997007784A3 (en) LIPOSOMAL PHOSPHODIESTER, PHOSPHOROTHIOATE, AND p-ETHOXY OLIGONUCLEOTIDES
AU9023798A (en) Mdm2-specific antisense oligonucleotides
AU8280798A (en) An improved method for design and selection of efficacious antisense oligonucleotides
ZA9811948B (en) Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom.
AU9663398A (en) Prize redemption system for games
AU3222795A (en) Antitumor antisense oligonucleotides
GB9510718D0 (en) Antisense oligonucleotides
AU2946295A (en) Targeted gene delivery system
IL118419A0 (en) Delivery vehicles comprising stable lipid/nucleic acid complexes
AU3745297A (en) Central random number generation for gaming system
AU6617898A (en) An antisense oligonucleotide preparation method
AU6185096A (en) Bingo game management method
AU5883498A (en) Computerised gaming system
AU6535096A (en) Methods and means for targeted gene delivery
AU3104597A (en) Phosphotriester oligonucleotides, amidites and method of preparation
AU9380598A (en) Method for tabulating payout values for games of chance
AU5735098A (en) Instant, multiple play gaming ticket and validation system
AU8938098A (en) Liposomes containing oligonucleotides
AU3290997A (en) Cationic polymer/lipid nucleic acid delivery vehicles
AU1075199A (en) Multi-player entertainment system
AU3739697A (en) Gene delivery system
AU4565297A (en) Identifying antisense oligonucleotide binding
AU3811897A (en) Antisense oligonucleotides as antibacterial agents
AU5259498A (en) Antisense oligonucleotides
AU7073096A (en) Inhibited biological degradation of oligodeoxynucleotides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU BB BG CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU BB BG CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2228944

Country of ref document: CA

Ref country code: CA

Ref document number: 2228944

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1997 510642

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996929888

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996929888

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1996929888

Country of ref document: EP